Firms Should Look To Local CROs For Clinical Trials in Asia
This article was originally published in The Pink Sheet Daily
Asia medical consultant highlights advantages of China and India.
You may also be interested in...
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.
Establishment of the R&D site reflects Novartis’ commitment to the region, according to the drug maker.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.